English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: It is established that early insulin therapy can improve both β cell function and glycaemic control in newly diagnosed type 2 diabetic patients. The dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, can preserve or even increase the number of β cells in animal models of diabetes. Therefore, we aimed to determine whether treatment with sitagliptin after initial intensive insulin therapy would further reduce glycaemia and preserve β cell function in new-onset type 2 diabetes. Methods: 48 Chinese patients with newly diagnosed type 2 diabetes (fasting blood glucose concentration 13.42 ± 0.38 mmol/L; HbA1c:11.8 ± 0.2%) were recruited. All received insulin pump therapy for two weeks, followed by sitagliptin (100mg orally once daily) for three months. Arginine tests were performed at baseline, after two-weeks’ insulin pump therapy, and after 3 months’ sitagliptin therapy. Blood samples were collected at baseline, before and after the treatment with sitagliptin for measurement of blood glucose, plasma insulin and lipids profiles. β cell function was evaluated by HOMA-β and the insulin response to arginine. Results: Fasting blood glucose concentrations were substantially decreased after two weeks’ insulin therapy (P<0.01), and were further reduced after 3 months’ treatment with sitagliptin (P<0.01). HOMA-β and HOMA-IR were improved (P<0.01) after two weeks’ treatment with insulin, while HOMA-β was further improved after 3 months’ sitagliptin (P<0.01). However, the insulin response to arginine did not increase after two weeks’ insulin therapy, but did improve after sitagliptin (P<0.05). Conclusions: Intensive insulin therapy improved both glycaemic control and β cell function in newly diagnosed Chinese type 2 diabetes, and the improvements in β cell function was preserved after 3 months of sitagliptin.

Effect of Initial Intensive Insulin Therapy Followed by Sitagliptin on ? Cell Function in Patients with New Onset Type 2 Diabetes